Investing.com– Merck & Company Inc (NYSE:) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
The drugmaker is expected to pay $1.3 billion in cash for the ophthalmology firm, and could pay up to $1.7 billion in additional milestone payments, the WSJ reported, citing people with knowledge of the matter.
